4547:TYO
Kissei Pharmaceutical Co Ltd
JP¥3,885.00
arrow_upward
+1.44%(+55.00) 1D
ኖቬም 13, 3:30:00 ከሰዓት ጂ ኤም ቲ+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
JP¥3,860
High
JP¥3,885
Low
JP¥3,830
Mkt. cap
180.82 ቢ
Avg. vol.
85.82 ሺ
Volume
77.00 ሺ
Dividend
3.22%
Quarterly dividend
JP¥31
Ex-dividend date
30 ማርች 2027
P/E ratio
14.40
52-wk high
JP¥5,040
52-wk low
JP¥3,500
EPS
JP¥270
Shares outstanding
46.72 ሚ
No. of employees
2 ሺ
Open
JP¥3,860
High
JP¥3,885
Low
JP¥3,830
Mkt. cap
180.82 ቢ
Avg. vol.
85.82 ሺ
Volume
77.00 ሺ
Dividend
3.22%
Quarterly dividend
JP¥31
Ex-dividend date
30 ማርች 2027
P/E ratio
14.40
52-wk high
JP¥5,040
52-wk low
JP¥3,500
EPS
JP¥270
Shares outstanding
46.72 ሚ
No. of employees
2 ሺ
News stories
From web sources and news partners
24/7 Wall St.
·
ከ23 ደቂቃዎች በፊት
The S&P 500 Has a "Pure Value" Version. RPV Gives Its Cheapest Stocks the Biggest Weights
TradingNEWS
·
ከ24 ደቂቃዎች በፊት
Stock Market Today: S&P 500 7,510 (-1.1%), Nasdaq -1.9%, Dow DJI -0.3%; 7,845 Target as AMD -9.7%
24/7 Wall St.
·
ከ21 ደቂቃዎች በፊት
S&P 500 Slides Nearly 1% at Midday as Tech Absorbs Most of the Hit
TradingView
·
ከ3 ሰዓቶች በፊት
Wall Street Divided on S&P 500: Which ETFs Could Benefit in 2027?
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1.79 ሺ
Founded9 ኦገስ 1946
HeadquartersMatsumoto, Nagano, ጃፓን
SectorHealth Care
IndustryPharmaceutical industry
Websitekissei.co.jp